News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
279,691 Results
Type
Article (14898)
Company Profile (106)
Press Release (264679)
Multimedia
Podcasts (67)
Webinars (13)
Section
Business (89639)
Career Advice (550)
Deals (15568)
Drug Delivery (73)
Drug Development (37859)
Employer Resources (52)
FDA (6470)
Job Trends (6355)
News (153220)
Policy (14318)
Tag
2027 Genetown Elite (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (1)
Academia (556)
Accelerated approval (13)
Adcomms (10)
Allergies (67)
Alliances (23618)
ALS (63)
Alzheimer's disease (1020)
Antibody-drug conjugate (ADC) (103)
Approvals (6669)
Artificial intelligence (204)
Autoimmune disease (41)
Automation (12)
Bankruptcy (151)
Best Places to Work (4481)
BIOSECURE Act (9)
Biosimilars (118)
Biotechnology (42)
Bladder cancer (38)
Brain cancer (32)
Breast cancer (175)
Cancer (1355)
Cardiovascular disease (153)
Career advice (490)
Career pathing (17)
CAR-T (50)
CDC (6)
Cell therapy (154)
Cervical cancer (9)
Clinical research (32768)
Collaboration (740)
Compensation (327)
Complete response letters (33)
COVID-19 (805)
CRISPR (43)
C-suite (440)
Cystic fibrosis (58)
Data (1940)
Denatured (18)
Depression (46)
Diabetes (129)
Diagnostics (1461)
Digital health (8)
Diversity (2)
Diversity, equity & inclusion (14)
Drug discovery (115)
Drug pricing (116)
Drug shortages (12)
Duchenne muscular dystrophy (81)
Earnings (33929)
Editorial (20)
Employer branding (4)
Employer resources (51)
Events (39975)
Executive appointments (534)
FDA (7625)
Fibrodysplasia Ossificans Progressiva (4)
Friedreich's ataxia (2)
Frontotemporal dementia (3)
Funding (457)
Gene editing (70)
Generative AI (18)
Gene therapy (176)
GLP-1 (450)
Government (1449)
Grass and pollen (4)
Guidances (169)
Healthcare (3843)
HIV (11)
Huntington's disease (15)
IgA nephropathy (37)
Immunology and inflammation (69)
Immuno-oncology (14)
Indications (53)
Infectious disease (869)
Inflammatory bowel disease (73)
Inflation Reduction Act (7)
Influenza (24)
Intellectual property (115)
Interviews (75)
IPO (5995)
IRA (35)
Job creations (2073)
Job search strategy (430)
JPM (28)
Kidney cancer (9)
Labor market (28)
Layoffs (212)
Leadership (13)
Legal (3490)
Liver cancer (22)
Longevity (8)
Lung cancer (190)
Lymphoma (123)
Machine learning (13)
Management (21)
Manufacturing (416)
MASH (68)
Medical device (1370)
Medtech (1377)
Mergers & acquisitions (10005)
Metabolic disorders (444)
Multiple sclerosis (48)
NASH (14)
Neurodegenerative disease (151)
Neuropsychiatric disorders (40)
Neuroscience (1488)
Neurotech (1)
NextGen: Class of 2026 (1676)
Non-profit (702)
Now hiring (17)
Obesity (233)
Opinion (152)
Ovarian cancer (39)
Pain (112)
Pancreatic cancer (56)
Parkinson's disease (96)
Partnered (11)
Patents (224)
Patient recruitment (127)
Peanut (12)
People (30306)
Pharmaceutical (63)
Pharmacy benefit managers (18)
Phase 1 (8533)
Phase 2 (13941)
Phase 3 (12425)
Pipeline (1989)
Policy (137)
Postmarket research (1409)
Preclinical (3459)
Press Release (25)
Prostate cancer (86)
Psychedelics (17)
Radiopharmaceuticals (140)
Rare diseases (358)
Real estate (2695)
Recruiting (20)
Regulatory (11132)
Reports (15)
Research institute (649)
Resumes & cover letters (72)
Rett syndrome (5)
RNA editing (6)
RSV (20)
Schizophrenia (77)
Series A (83)
Series B (51)
Service/supplier (2)
Sickle cell disease (46)
Special edition (11)
Spinal muscular atrophy (82)
Sponsored (11)
Startups (1664)
State (2)
Stomach cancer (5)
Supply chain (50)
Tariffs (68)
The Weekly (47)
Vaccines (244)
Venture capital (33)
Weight loss (144)
Women's health (27)
Worklife (4)
Date
Today (25)
Last 7 days (169)
Last 30 days (712)
Last 365 days (10837)
2026 (1028)
2025 (11108)
2024 (12927)
2023 (14649)
2022 (20025)
2021 (20598)
2020 (19494)
2019 (15391)
2018 (12049)
2017 (14152)
2016 (13385)
2015 (15759)
2014 (12697)
2013 (10804)
2012 (11595)
2011 (12109)
2010 (11010)
Location
Africa (335)
Alabama (19)
Alaska (1)
Arizona (77)
Arkansas (3)
Asia (21235)
Australia (2775)
California (3277)
Canada (1495)
China (569)
Colorado (143)
Connecticut (135)
Delaware (123)
Europe (41501)
Florida (615)
Georgia (64)
Hawaii (1)
Idaho (10)
Illinois (356)
India (44)
Indiana (242)
Iowa (2)
Japan (269)
Kansas (78)
Kentucky (20)
Louisiana (4)
Maine (2)
Maryland (445)
Massachusetts (2702)
Michigan (46)
Minnesota (165)
Mississippi (1)
Missouri (36)
Montana (8)
Nebraska (7)
Nevada (17)
New Hampshire (9)
New Jersey (1447)
New Mexico (8)
New York (1040)
North Carolina (627)
North Dakota (2)
Northern California (1492)
Ohio (81)
Oklahoma (5)
Oregon (18)
Pennsylvania (747)
Puerto Rico (13)
Rhode Island (17)
South America (527)
South Carolina (10)
Southern California (1433)
Tennessee (60)
Texas (465)
United States (13201)
Utah (61)
Virginia (160)
Washington D.C. (42)
Washington State (239)
West Virginia (1)
Wisconsin (40)
Wyoming (1)
279,691 Results for "sigma tau pharmaceuticals".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Alzheimer’s disease
J&J’s Anti-Tau Bet Falls Flat in Mid-Stage Alzheimer’s Trial
Johnson & Johnson will discontinue the Phase II Auτonomy study of posdinemab after a scheduled review found the anti-tau antibody failed to slow clinical decline in patients with early Alzheimer’s disease.
November 24, 2025
·
1 min read
·
Heather McKenzie
Alzheimer’s disease
Eisai Still Confident in Anti-Tau Asset as J&J Becomes Latest Victim in Spiraling Space
Days after Johnson & Johnson’s posdinemab failed to slow clinical decline in patients with Alzheimer’s disease, Eisai Chief Clinical Officer Lynn Kramer expressed unwavering conviction in his company’s own anti-tau asset, while others suggest the Alzheimer’s field is heading in a completely different direction.
December 5, 2025
·
4 min read
·
Heather McKenzie
Alzheimer’s disease
Biogen’s Much Anticipated Tau Readout in Alzheimer’s Will Spur More Questions
Analysts, investors and scientists are eager for Biogen’s 2026 BIIB080 readout. Even if successful, executives warn that there are many more steps before the Alzheimer’s therapy could reach the market.
February 9, 2026
·
4 min read
·
Annalee Armstrong
Press Releases
Alpha Tau to Participate in December 2025 Investor Conferences
December 2, 2025
·
1 min read
Press Releases
Alpha Tau to Present at the J.P. Morgan 2026 Healthcare Conference
December 19, 2025
·
1 min read
Press Releases
Tonix Pharmaceuticals Announces Licensing TNX-4900, a Selective Sigma-1 Receptor Antagonist for Chronic Neuropathic Pain from Rutgers University
December 16, 2025
·
12 min read
Press Releases
Nautilus Biotechnology Launches Early Access Program for Novel Single-Molecule Proteomics Platform, Starting with Tau Proteoforms Assay
January 8, 2026
·
6 min read
Press Releases
Alpha Tau to Participate at Jefferies 2025 Global Healthcare Conference in London
November 11, 2025
·
1 min read
Press Releases
Eisai Presents New Data on Anti-Tau Antibody Etalanetug (E2814) at CTAD 2025
December 2, 2025
·
4 min read
Press Releases
Alpha Tau Receives FDA Approval to Initiate a Trial for Patients with Locally Recurrent Prostate Cancer
December 3, 2025
·
5 min read
1 of 27,970
Next
